1. Ahn C, Gustafson C, Sandoval L, Davis S, Feldman S (2013) Cost Effectiveness of Biologic Therapies for Plaque Psoriasis. Am J Clin Dermatol 14:315–326
2. Anis AH, Bansback N, Sizto S, Gupta SR, Willian MK, Feldman SR (2010) Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States. J Dermatolog Treat 22:65–74
3. Augustin M, Christina Spehr, Radtke M, Boehncke WH, Thomas Luger, Ulrich Mrowietz, Michael Reusch (2014) German psoriasis registry PsoBest: objectives, methodology and baseline data. JDDG J der Deutschen Dermatologischen Gesellschaft 12:48–57
4. Boehncke WH, Boehncke S (2008) Cardiovascular morbidity in psoriasis: epidemiology, pathomechanisms, and clinical consequences. G Ital Dermatol Venereol 143:307–313
5. Briggs A, Claxton K, Sculpher M (2006) Decision modelling for health economic evaluation. Oxford University Press, Oxford